Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Di, Jiabo ^a   Massuger, Leon F A G ^b   De Boer, Tjitske Duiveman ^a   Zusterzeel, Petra L M ^b   Figdor, Carl G ^a   Torensma, Ruurd ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD4; CD8; IP 10; ovarian cancer; Proliferation; Stem cell markers

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4;

ARTICLE; ASCITES; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYSOSOME; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION;

EID: 84886945717     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24271     Document Type: Article

References (67)

1. Rutkowski MR, Stephen TL, Conejo-Garcia JR. Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol 2012; 278:21-6; PMID:23121972; http://dx.doi.org/10.1016/j.cellimm. 2012.06.014
2. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy 2011; 3:539-56; PMID:21463194; http://dx.doi.org/10.2217/imt.11.20
3. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; PMID:22214470; http://dx.doi. org/10.1186/1479-5876-10-1
4. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving firstline, platinum-based chemotherapy. Gynecol Oncol 2008; 108:421-7; PMID:18036640; http://dx.doi. org/10.1016/j.ygyno.2007.10.018
5. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 2004; 53:176-86; PMID:14685782; http://dx.doi. org/10.1007/s00262-003-0478-4
6. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9:4296-303; PMID:14555498
7. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474:212-5; PMID:21572395; http://dx.doi.org/10.1038/nature10135
8. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:3-15; PMID:11315507; http://dx.doi.org/10.1007/s002620000169
9. WolflM, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007; 110:201-10; PMID:17371945; http://dx.doi.org/10.1182/blood-2006-11-056168
10. Cannons JL, Lau P, Ghumman B, De Benedette MA, Yagita H, Okumura K, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001; 167:1313-24; PMID:11466348
11. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168:4897-906; PMID:11994439
12. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2:735-47; PMID:12360212; http://dx.doi.org/10.1038/nri911
13. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882; http://dx.doi.org/10.1016/S0022-1759(03)00265-5
14. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-89; PMID:14525967; http://dx.doi.org/10.1189/jlb.0603252
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8; PMID:12629218; http://dx.doi. org/10.1073/pnas.0530291100
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730
17. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-51; PMID:16322242; http://dx.doi.org/10.1158/0008-5472.CAN-05-2018
18. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875-83; PMID:19816957
19. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104:10158-63; PMID:17548814; http://dx.doi. org/10.1073/pnas.0703478104
20. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumorinitiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9:357-65; PMID:21982235; http://dx.doi.org/10.1016/j. stem.2011.08.010
21. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328-37; PMID:16230395; http://dx.doi. org/10.1158/0008-5472.CAN-05-1343
22. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23; PMID:18371365; http://dx.doi.org/10.1016/j. stem.2007.06.002
23. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456:593-8; PMID:19052619; http://dx.doi. org/10.1038/nature07567
24. Rasheed Z, Wang Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010; PMID:20972397; http://dx.doi. org/10.3791/2169
25. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8; PMID:14522905
26. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311-20; PMID:18519691; http://dx.doi.org/10.1158/0008-5472.CAN-08-0364
27. Looijenga LH, Stoop H, De Leeuw HP, De Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63:2244-50; PMID:12727846
28. Medvedev SP, Shevchenko AI, Mazurok NA, Zakiian SM. OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells. Genetika 2008; 44:1589-608; PMID:19178078
29. Zangrossi S, Marabese M, Broggini M, Giordano R, D'Erasmo M, Montelatici E, et al. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 2007; 25:1675-80; PMID:17379765; http://dx.doi.org/10.1634/stemcells. 2006-0611
30. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004; 28:935-40; PMID:15223965; http://dx.doi. org/10.1097/00000478-200407000-00014
31. Dhodapkar MV. Immunity to stemness genes in human cancer. Curr Opin Immunol 2010; 22:245-50; PMID:20144857; http://dx.doi.org/10.1016/j. coi.2010.01.011
32. Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010; 107:8718-23; PMID:20404147; http://dx.doi.org/10.1073/pnas.0915086107
33. Li Y, Kurlander RJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med 2010; 8:104; PMID:20977748; http://dx.doi.org/10.1186/1479-5876-8-104
34. Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C. CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology 2013; 138:165-72; PMID:23113658
35. Wang HY, Wang RF. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol 2012; 114:151-76; PMID:22449781; http://dx.doi.org/10.1016/B978-0-12-396548-6.00006-8
36. Bakker AB, Schreurs MW, De Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineagespecific antigen gp100 is recognized by melanomaderived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-9; PMID:8113668; http://dx.doi. org/10.1084/jem.179.3.1005
37. Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett 1994; 40:171-8; PMID:8088874; http://dx.doi. org/10.1016/0165-2478(94)90189-9
38. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961-8; PMID:7706734
39. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55:4972-9; PMID:7585538
40. Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit Rev Immunol 2001; 21:263-73; PMID:11642608; http://dx.doi. org/10.1615/CritRevImmunol.v21.i1-3.170
41. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001; 98:14565-70; PMID:11734652; http://dx.doi. org/10.1073/pnas.251140998
42. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof?.Crit Rev Oncol Hematol 2008; 66:118-34; PMID:18262431; http://dx.doi.org/10.1016/j.critrevonc.2007.12.007
43. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, De Boer A, et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009; 69:2927-34; PMID:19318559; http://dx.doi.org/10.1158/0008-5472.CAN-08-3920
44. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102-10; PMID:23010076; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479
45. Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20:1063-74; PMID:22371843; http://dx.doi.org/10.1038/mt.2012.11
46. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28:1131-8; PMID:22895835
47. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx.doi.org/10.1038/nature11538
48. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423-34; PMID:21697280; http://dx.doi. org/10.1158/0008-5472.CAN-11-0367
49. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930
50. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366-72; PMID:20144842; http://dx.doi. org/10.1016/j.ygyno.2010.01.019
51. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67:8900-5; PMID:17875732; http://dx.doi.org/10.1158/0008-5472.CAN-07-1866
52. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
53. Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010; 107:8718-23; PMID:20404147; http://dx.doi.org/10.1073/pnas.0915086107
54. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204:831-40; PMID:17389240; http://dx.doi. org/10.1084/jem.20062387
55. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, et al. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol 2011; 2011:302145
56. Zhao P, Liu C, Xu K, Zheng S, Li H, Xu Y, et al. Expression of OCT4 protein in bladder cancer and its clinicopathological implications. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32:643-6; PMID:22588915
57. Xu K, Zhu Z, Zeng F. Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci 2007; 27:675-7; PMID:18231740; http://dx.doi.org/10.1007/s11596-007-0614-z
58. Singh S, Trevino JG, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stemlike side-population cells in non-small cell lung cancer. Mol Cancer 2012; 11:73; PMID:23009336; http://dx.doi.org/10.1186/1476-4598-11-73
59. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to selfrenewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287:32800-24; PMID:22847005; http://dx.doi.org/10.1074/jbc. M111.308528
60. Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010; 24:916-32; PMID:20382729; http://dx.doi.org/10.1101/gad.1899710
61. Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y, et al. Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol 2011; 223:672-82; PMID:21341266; http://dx.doi. org/10.1002/path.2827
62. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 2011; 59:763-75; PMID:22014056; http://dx.doi.org/10.1111/j.1365-2559.2011.03993.x
63. Prud'homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 2012; 18:2838-49; PMID:22390767
64. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40:621-8; PMID:21342274; http://dx.doi.org/10.1111/j.1600-0714.2011.01015.x
65. Hu L., McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102:1276-83; PMID:20354527; http://dx.doi.org/10.1038/sj.bjc.6605626
66. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29:2672-80; PMID:20190812; http://dx.doi. org/10.1038/onc.2010.35
67. Zhi-Iong Ma J, Yang J, Qin JS, Richter A, Perret R, El-Deiry WS, et al. Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. Oncoimmunology 2012; 1:1507-16; PMID:23264897; http://dx.doi. org/10.4161/onci.22128